Here's Why This Biotechnology Skyrocketed by 439% in December

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an exciting new treatment.Capricor Therapeutics (CAPR 2.85%) stock rose an incredible 439.4% in December, according to data provided by S&P Global Market Intelligence. The move followed the company's announcement of positive top-line results from a Phase 3 trial of Deramiocel, a cell therapy for the treatment of Duchenne muscular dystrophy (DMD). However, the story is not quite as simple as a ...